

University of Groningen

Plasma ApoE elevations are associated with NAFLD

van den Berg, Eline H.; Corsetti, James P.; Bakker, Stephan J. L.; Dullaart, Robin P. F.

Published in:
 PLoS ONE

DOI:
[10.1371/journal.pone.0220659](https://doi.org/10.1371/journal.pone.0220659)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van den Berg, E. H., Corsetti, J. P., Bakker, S. J. L., & Dullaart, R. P. F. (2019). Plasma ApoE elevations are associated with NAFLD: The PREVEND Study. *PLoS ONE*, 14(8), [0220659].
<https://doi.org/10.1371/journal.pone.0220659>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Plasma ApoE elevations are associated with NAFLD: The PREVEND Study

Eline H. van den Berg^{1,2*}, James P. Corsetti³, Stephan J. L. Bakker⁴, Robin P. F. Dullaart¹

1 Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, **2** Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, **3** Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America, **4** Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

* e.h.van.den.berg@umcg.nl



OPEN ACCESS

Citation: van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF (2019) Plasma ApoE elevations are associated with NAFLD: The PREVEND Study. PLoS ONE 14(8): e0220659. <https://doi.org/10.1371/journal.pone.0220659>

Editor: Petter Bjornstad, University of Colorado Denver School of Medicine, UNITED STATES

Received: March 26, 2019

Accepted: July 20, 2019

Published: August 6, 2019

Copyright: © 2019 van den Berg et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The Dutch Kidney Foundation supported the infrastructure of the PREVEND program from 1997 to 2003 (Grant E.033). The University Medical Center Groningen supported the infrastructure from 2003 to 2006. Dade Behring, Ausam, Roche, and Abbott financed laboratory equipment and reagents by which various laboratory determinations could be performed. The Dutch Heart Foundation supported studies on lipid

Abstract

Non-alcoholic fatty liver disease (NAFLD) is featured by increased plasma very low density lipoproteins (VLDL). The extent to which plasma apolipoprotein E (ApoE) levels are elevated in NAFLD is unclear. We determined whether plasma ApoE is elevated in subjects with suspected NAFLD. Plasma ApoE and genotypes were determined in 6,762 participants of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) cohort. A Fatty Liver Index (FLI) ≥ 60 was used as a proxy of NAFLD. A total of 1,834 participants had a FLI ≥ 60 , which coincided with increased triglycerides, non-HDL cholesterol, ApoB and ApoE (all $P < 0.001$). In multivariable linear regression analysis, plasma ApoE levels were positively associated with an elevated FLI when taking account of ApoE genotypes and other clinical and laboratory covariates (fully adjusted model: $\beta = 0.201$, $P < 0.001$). Stratified analysis for ApoE genotypes (ApoE $\epsilon 3\epsilon 3$ homozygotes, ApoE $\epsilon 2$ carriers, and ApoE $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$ carriers combined), also showed positive associations of plasma ApoE levels with an elevated FLI in each group (all $P < 0.001$). In conclusion, it is suggested that NAFLD is characterized by increased plasma ApoE levels, even when taking account of the various ApoE genotypes. Increased plasma ApoE may contribute to altered VLDL metabolism and to increased atherosclerosis susceptibility in NAFLD.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of alcohol abuse, and is emerging as the most common cause of chronic liver disease. The spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis [1–3]. NAFLD is considered to be the liver manifestation of the metabolic syndrome (MetS) and coincides with an increased risk for the development of type 2 diabetes mellitus (T2D) [1,3–5]. Furthermore, NAFLD is characterized by plasma lipoprotein abnormalities, including elevations in apolipoprotein (Apo)B-containing lipoproteins and

metabolism (Grant 2001-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

decreased levels of high density lipoprotein (HDL) cholesterol [6–8], which predispose to atherosclerotic cardiovascular disease (CVD) [9,10]. Hepatic fat accumulation is regarded as the driving force of enhanced production of very low-density lipoproteins (VLDL) by the liver, resulting in an increased plasma concentration of large VLDL particles and consequently in higher triglycerides [11–14].

Apolipoprotein E (ApoE) is a 34 kDA protein comprised of 299 amino acids [15]. The liver is a major source of circulating ApoE [16,17]. ApoE plays an important role in the production of VLDL as well as in their clearance by facilitating the hepatic uptake of triglyceride-rich lipoproteins (TRL) via ApoE-mediated binding of TRL remnants to hepatic lipoprotein receptors [18–21]. ApoE may also contribute to inhibition of inflammation and oxidative stress [22]. In plasma, ApoE is strongly associated with VLDL and hence with triglycerides [23–26]. Higher total plasma ApoE levels are also observed in MetS [27], and may confer increased CVD risk, though unlikely independent of ApoB [28]. Additionally, ApoE was observed to be associated with CVD in women with elevated HDL cholesterol in combination with high C-reactive protein (CRP) levels [29,30].

The *APOE* gene is located on chromosome 19 and has 3 common alleles ($\epsilon 2$, $\epsilon 3$ and $\epsilon 4$) leading to six ApoE genotypes; three homozygotes ($\epsilon 2\epsilon 2$, $\epsilon 3\epsilon 3$ and $\epsilon 4\epsilon 4$) and three heterozygotes ($\epsilon 2\epsilon 4$, $\epsilon 2\epsilon 3$, $\epsilon 3\epsilon 4$) [31,32]. ApoE polymorphisms account in part for the variability of plasma ApoE with the lowest levels in ApoE $\epsilon 4$ carriers [33], and are known to affect lipoprotein receptor-binding abilities. A direct effect of ApoE genotypes on total cholesterol and low density lipoprotein cholesterol (LDL-C) is well established [33,34]. Furthermore, a meta-analysis showed a linear relationship between ApoE genotypes and coronary risk [35], emphasizing the importance of ApoE gene variation for atherosclerosis development.

Conversely, ApoE could also be involved in the development of hepatic fat accumulation. In diet-induced NAFLD murine models, ApoE deficiency was suggested to retard hepatic lipid deposition [36]. In ApoE deficient mice, a Western high-fat cholesterol-rich diet accelerates the formation of NASH with fibrosis [37], but the association of plasma ApoE levels with NAFLD has not been previously tested in humans. Additionally, several small-scale studies reported on the possible association of ApoE genotypes with NAFLD but showed conflicting results [38–43].

Since ApoE may affect VLDL metabolism, it is plausible to hypothesize that NAFLD is featured by higher plasma ApoE levels. In the absence of previous reports on the possible impact of NAFLD on plasma ApoE, we initiated the present study to examine whether increased plasma ApoE levels relate to prevalent NAFLD. We also questioned whether such an association is affected by ApoE genotypes. To this end we carried out a cross-sectional analysis among 6,762 subjects participating in the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort study, comprising a large and well-characterized population from the north of the Netherlands.

Materials and methods

Study population

The study was performed among participants of the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort study [44,45]. PREVEND is a large prospective general population-based study, that was initiated to investigate cardiovascular and renal disease with a focus on albuminuria. All inhabitants (28 to 75 years old) of Groningen, the Netherlands were sent a questionnaire on demographics and cardiovascular morbidity and were asked to supply an early morning urine specimen. Pregnant women, type 1 diabetic subjects and type 2 diabetic subjects using insulin were not allowed to participate. All participants with a urinary

albumin concentration ≥ 10 mg/L were invited to our clinic together with randomly selected subjects with a urinary albumin concentration < 10 mg/L. The initial study population of the PREVENT study comprised 8,592 subjects who completed the total study screening program. The PREVENT study was approved by the Medical Ethics Committee of the University Medical Center Groningen and is performed in accordance with Declaration of Helsinki guidelines [44,45]. All participants gave written informed consent.

For the present study, we excluded subjects in which data on plasma ApoE, clinical and biochemical variables to calculate the Fatty Liver Index (FLI), a proxy of NAFLD, were not available, leaving a study population of 6,762 participants.

Measurements and definitions

Measurements and definitions are reported as described in detail previously [46]. Body mass index (BMI) was calculated as weight (kg) divided by height squared (meter). Waist circumference was measured as the smallest girth between rib cage and iliac crest. The waist/hip ratio was determined as the waist circumference divided by the largest girth between waist and thigh [44]. Blood pressure was measured using an automatic device. T2D was defined as a fasting glucose ≥ 7.0 mmol/L, a random glucose ≥ 11.1 mmol/L, self-report of a physician diagnosis or the use of glucose lowering drugs. Alcohol consumption was recorded with one alcoholic drink being assumed to contain 10 grams of alcohol. Smoking was categorized into current and never/former smokers. Past cardiovascular history included: hospitalization for myocardial ischemia, obstructive coronary artery disease or revascularization procedures. Urinary albumin excretion (UAE) was measured as described in two 24-hour urine collections and the results were averaged for analysis [44]. Estimated glomerular filtration rate (eGFR) was calculated applying the combined creatinine cystatin C-based Chronic Kidney Disease Epidemiology Collaboration equation [47]. Information on medication use was combined with information from a pharmacy-dispensing registry, which has complete information on drug usage of $> 95\%$ of subjects in the PREVENT study. Venous blood samples were drawn after an overnight fast while the participants had rested for 15 minutes.

For the diagnosis of suspected NAFLD, the algorithm of the Fatty Liver Index (FLI) was used [48]. The FLI was calculated according to the following formula [48]:

$$\left[e \left(0.953 \times \log_e (\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log_e (\text{GGT}) + 0.053 \times \text{waist circumference} - 15.745 \right) / \left[1 + e \left(0.953 \times \log_e (\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \log_e (\text{GGT}) + 0.053 \times \text{waist circumference} - 15.745 \right) \right] \right] \times 100,$$

where GGT is gamma-glutamyltransferase.

The optimal cut-off value for the FLI is documented to be 60 with an accuracy of 84%, a sensitivity of 61% and a specificity of 86% for detecting suspected NAFLD as determined by ultrasonography [48]. $\text{FLI} \geq 60$ was therefore used as proxy of NAFLD. The FLI is currently considered as one of the best-validated steatosis scores for larger scale screening studies [49]. Alternatively, we used the Hepatic Steatosis Index (HSI) which has thus far predominantly been used in Asian populations [50]. The HSI is defined as follows:

$$\text{HSI} = 8 \times \text{ALT/AST ratio} + \text{BMI} \left(+ 2, \text{ if diabetes}; +2, \text{ if female} \right),$$

where ALT is alanine aminotransferase and AST is aspartate aminotransferase.

The cut-off value of the HSI for detecting suspected NAFLD is 36 [50]. In these equations, BMI is expressed in kg/m^2 , triglycerides are expressed in mmol/L, and GGT, ALT and AST are expressed in U/L.

The MetS was defined according to the revised National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III criteria [51]. Participants were categorized with MetS when at least three out of five of the following criteria were present: waist circumference > 102 cm for men and > 88 cm for women; plasma triglycerides ≥ 1.7 mmol/L; HDL cholesterol < 1.0 mmol/L for men and < 1.3 mmol/L for women; hypertension (blood pressure $\geq 130/85$ mm Hg or the use of antihypertensive medication); hyperglycemia (fasting glucose ≥ 5.6 mmol/L or the use of glucose lowering drugs).

Laboratory methods

Laboratory methods are reported as described in detail previously [46]. Heparinized plasma and serum samples were obtained by centrifugation at $1400\times g$ for 15 min at 4°C . Plasma and serum samples were stored at -80°C until analysis. Glucose was measured directly after blood collection. Plasma total cholesterol, triglycerides, HDL cholesterol, Apo A-I, ApoB and ApoE were measured as previously described [28–30,44,45]. ApoE genotyping was performed as described previously [52]. Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol. LDL cholesterol was calculated by the Friedewald formula if triglycerides were < 4.5 mmol/L [53]. Serum ALT and AST were measured using the standardized kinetic method with pyridoxal phosphate activation (Roche Modular P; Roche Diagnostics, Mannheim, Germany). Serum GGT was assayed by an enzymatic colorimetric method (Roche Modular P, Roche Diagnostics, Mannheim, Germany). Standardization of ALT, AST and GGT was performed according to International Federation of Clinical Chemistry guidelines [54–56]. hsCRP was assayed by nephelometry. Serum creatinine was measured by an enzymatic method on a RocheModular analyzer (Roche Diagnostics, Mannheim, Germany). Serum cystatin C was measured by Gentian Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a Modular analyzer (Roche Diagnostics). Urinary albumin was measured by nephelometry (Dade Behring Diagnostic, Marburg, Germany).

Statistical analysis

IBM SPSS software (version 23.0 Armonk, NY: IBM Corp) was used for data analysis. Results are expressed as mean \pm standard deviation (SD), median with interquartile range (IQR) or as numbers (percentages). Normality of distribution was assessed and checked for skewness. Between group differences in variables were determined by unpaired T-tests for normally distributed variables, Mann-Whitney U test for non-normally distributed variables or by Chi-square tests for categorical variables where appropriate. Multivariable linear regression analyses were carried out to disclose the independent associations of ApoE levels with an elevated FLI and HSI when taking account of clinical covariates and laboratory parameters, including ApoE genotype. Stratified analyses were additionally performed in ApoE $\epsilon 3$ homozygotes, ApoE $\epsilon 2$ carriers ($\epsilon 2\epsilon 2$, $\epsilon 2\epsilon 3$ and $\epsilon 2\epsilon 4$ genotypes combined) and ApoE $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$ carriers combined. Two-sided *P*-values < 0.05 were considered significant.

Results

Clinical and laboratory characteristics of the study population

The study population consisted of 6,762 subjects of whom 1,834 (27.1%) were classified with a FLI ≥ 60 , as proxy of NAFLD. Table 1 shows the clinical characteristics and laboratory data of the participants according to the FLI categorization. Relatively more men had a FLI ≥ 60 (men 68.8% vs. women 31.2%). Subjects with a FLI ≥ 60 were more likely to be classified with MetS and T2D, and had a cardiovascular history more frequently. Antihypertensive medication, and

Table 1. Clinical and laboratory characteristics including plasma apolipoprotein E in 4,928 subjects with a Fatty Liver Index (FLI) < 60 and 1,834 subjects with a FLI ≥ 60.

	FLI < 60 n = 4,928 (72.9)	FLI ≥ 60 n = 1,834 (27.1)	P
Age (years), mean ± SD	47.8 ± 12.5	55.2 ± 11.6	<0.001
Sex (men/women), n (%)	2,100 (42.6) / 2,828 (57.4)	1,261 (68.8) / 573 (31.2)	<0.001
T2D , n (%)	86 (1.7)	158 (8.6)	<0.001
MetS , n (%)	414 (8.4)	1,142 (62.3)	<0.001
History of cardiovascular disease , n (%)	178 (3.6)	167 (9.1)	<0.001
Current smokers , n (%)	1,661 (33.7)	602 (32.8)	0.54
Alcohol ≥10 g/day , n (%)	1,172 (23.8)	552 (30.1)	<0.001
Antihypertensive medication , n (%)	509 (10.3)	532 (29.0)	<0.001
Glucose lowering drugs , n (%)	54 (1.1)	69 (3.8)	<0.001
Lipid lowering drugs , n (%)	212 (4.3)	208 (11.3)	<0.001
Systolic blood pressure (mm Hg), mean ± SD	125 ± 19	141 ± 20	<0.001
Diastolic blood pressure (mm Hg), mean ± SD	72 ± 9	79 ± 9	<0.001
BMI (kg/m ²), mean ± SD	24.4 ± 2.90	30.5 ± 3.92	<0.001
Waist circumference , mean ± SD	82.9 ± 9.6	102.9 ± 8.9	<0.001
Waist/hip ratio , mean ± SD	0.85 ± 0.08	0.96 ± 0.08	<0.001
Glucose (mmol/L), mean ± SD	4.63 ± 0.83	5.35 ± 1.48	<0.001
hsCRP (mg/L), median (IQR)	0.97 (0.44–2.32)	2.35 (1.19–4.78)	<0.001
ALT (U/L), median (IQR)	18 (14–24)	28 (20–39)	<0.001
AST (U/L), median (IQR)	23 (20–27)	27 (23–32)	<0.001
GGT (U/L), median (IQR)	20 (14–28)	41 (29–65)	<0.001
eGFR (ml/min/1.73 m ²), mean ± SD	97.0 ± 16.5	88.9 ± 17.8	<0.001
UAE (mg/24 hr), median (IQR)	8.4 (6.0–14.0)	14.0 (8.0–32.3)	<0.001
Total cholesterol (mmol/L), mean ± SD	5.46 ± 1.09	6.08 ± 1.08	<0.001
Non-HDL cholesterol (mmol/L), mean ± SD	4.04 ± 1.13	4.98 ± 1.09	<0.001
LDL cholesterol (mmol/L), mean ± SD	3.54 ± 1.03	4.07 ± 1.02	<0.001
HDL cholesterol (mmol/L), mean ± SD	1.42 ± 0.40	1.11 ± 0.30	<0.001
Triglycerides (mmol/L), median (IQR)	1.00 (0.76–1.33)	1.84 (1.36–2.48)	<0.001
ApoA-I (g/L), mean ± SD	1.420 ± 0.302	1.304 ± 0.272	<0.001
ApoB (g/L), mean ± SD	0.972 ± 0.284	1.185 ± 0.307	<0.001
ApoE (g/L), mean ± SD	0.036 ± 0.012	0.045 ± 0.017	<0.001
ApoE genotype			0.19
ApoE genotype ε2ε2 , n (%)	29 (0.6)	19 (1.0)	
ApoE genotype ε2ε3 , n (%)	566 (11.5)	233 (12.7)	
ApoE genotype ε2ε4 , n (%)	116 (2.4)	47 (2.6)	
ApoE genotype ε3ε3 , n (%)	2,633 (53.4)	944 (51.5)	
ApoE genotype ε3ε4 , n (%)	1,163 (23.6)	431 (23.5)	
ApoE genotype ε4ε4 , n (%)	124 (2.5)	39 (2.1)	

Data are given in number with percentages (%), mean ± standard deviation (SD) for normally distributed data or median with interquartile ranges (IQR) for non-normally distributed data. Abbreviations: ALT, alanine aminotransferase; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; ApoE, apolipoprotein E; AST, aspartate aminotransferase; AU, arbitrary units; BMI, body mass index; FLI, Fatty Liver Index; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyltransferase; HDL, high density lipoproteins; hsCRP, high sensitivity C-reactive protein; LDL, low density lipoproteins; MetS, metabolic syndrome; T2D, type 2 diabetes mellitus; UAE, urinary albumin excretion. LDL cholesterol was calculated by the Friedewald formula in 4,903 subjects with a FLI < 60 and in 1,735 subjects with a FLI ≥ 60.

<https://doi.org/10.1371/journal.pone.0220659.t001>

glucose and lipid lowering drugs were taken more frequently in subjects with a FLI ≥ 60 . Alcohol consumption ≥ 10 gram/day was recorded in subjects with an elevated FLI more frequently, but cigarette smoking was not different between subjects with and without an elevated FLI. BMI, waist circumference, the waist/hip ratio, systolic and diastolic blood pressure, plasma glucose, hsCRP, ALT, AST, GGT, UAE, total cholesterol, non-HDL cholesterol, LDL cholesterol and triglycerides were higher in subjects with an elevated FLI, but eGFR and HDL cholesterol were lower in subjects with an elevated FLI (Table 1). ApoE and ApoB were higher, whereas ApoA-I was lower in subjects with an elevated FLI ($P < 0.001$ for each). ApoE genotype distribution was not significantly different between subjects (multinomial Chi-square, $P = 0.19$). Both in subjects with and without an elevated FLI, ApoE genotype $\epsilon 3\epsilon 3$ was most frequent, followed by a descending frequency of $\epsilon 3\epsilon 4$, $\epsilon 2\epsilon 3$, $\epsilon 2\epsilon 4$, $\epsilon 4\epsilon 4$ and $\epsilon 2\epsilon 2$ ApoE genotypes (Table 1).

Independent relationships of plasma ApoE with an elevated FLI and HSI

Multivariable linear regression analyses were subsequently performed in order to establish the extent to which plasma ApoE was associated with an elevated FLI (Table 2). In age- and sex-adjusted analysis a positive association of plasma ApoE with an elevated FLI was found (Table 2, Model 1, $\beta = 0.299$, $P < 0.001$). This association of plasma ApoE with an elevated FLI remained present after adjustment for T2D, MetS, alcohol intake, current smoking and the various ApoE genotypes (Table 2, Model 2, $\beta = 0.206$, $P < 0.001$). When further adjusted for eGFR, UAE, a cardiovascular disease history and use of antihypertensive medication and glucose and lipid lowering drugs, plasma ApoE remained associated with an elevated FLI (Table 2, Model 3, $\beta = 0.201$, $P < 0.001$). Plasma ApoE was also associated with an elevated FLI in alternative analysis adjusted for glucose, non-HDL cholesterol and HDL cholesterol (Table 2, Model 4, $\beta = 0.181$, $P < 0.001$) or for glucose, ApoB and ApoA-1 (Table 2, Model 5, $\beta = 0.204$, $P < 0.001$). Furthermore, these analyses demonstrated higher ApoE levels in the context of MetS, higher non-HDL cholesterol, HDL cholesterol, ApoB and ApoA-1 as well as higher ApoE levels in $\epsilon 2$ carriers and lower ApoE levels in $\epsilon 4$ carriers (Table 2, Models 2–5). In an alternative analysis with an elevated HSI instead of an elevated FLI, a similar independent positive association of plasma ApoE with an elevated HSI was found (Table 3, all models, $P < 0.001$). Moreover, in analysis with HSI and triglycerides as independent variables, ApoE was associated with an elevated HSI ($\beta = 0.029$, $P = 0.003$) independent of triglycerides. Additionally, analysis with comparison of an elevated FLI ≥ 60 with FLI < 30 (S1 Table) and elevated HSI > 36 with HSI < 30 (S2 Table), as a lower cut-off for excluding suspected NAFLD, showed even stronger associations with plasma ApoE.

A sensitivity analysis with exclusion of subjects with alcoholic intake ≥ 10 g/day, a positive cardiovascular history, impaired eGFR (< 60 mL/min/1.73 m²), elevated UAE (> 30 mg/24 hr), use of antihypertensive drugs, glucose and lipid lowering drugs, leaving 3,501 subjects for analysis, also demonstrated a positive association of plasma ApoE levels with an elevated FLI when taking account of T2D, MetS, smoking and ApoE genotype (Table 4, all models $P < 0.001$).

Stratified analyses according to ApoE genotype showed significant associations of ApoE with an elevated FLI in ApoE $\epsilon 3\epsilon 3$ homozygotes (S3 Table), ApoE $\epsilon 2$ carriers ($\epsilon 2\epsilon 2$, $\epsilon 2\epsilon 3$ and $\epsilon 2\epsilon 4$ genotypes combined) (S4 Table) and a combination of genotype ApoE $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$ (S5 Table) ($P < 0.001$ for each genotype group and $P < 0.001$ in all models).

Discussion

The present large-scale cross-sectional study in a predominantly Caucasian population demonstrates to the best of our knowledge for the first time that plasma ApoE levels, a well-

Table 2. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) (≥ 60) after adjustment for clinical and laboratory covariates in 6,762 subjects.

	Model 1		Model 2		Model 3		Model 4		Model 5	
	β	P	β	P	β	P	β	P	β	P
Age	0.124	< 0.001	0.095	< 0.001	0.097	< 0.001	-0.025	0.057	0.019	0.146
Sex (men vs. women)	-0.030	0.010	0.004	0.785	0.005	0.730	-0.011	0.408	-0.006	0.681
FLI ≥ 60 vs. < 60	0.299	< 0.001	0.206	< 0.001	0.201	< 0.001	0.181	< 0.001	0.204	< 0.001
T2D (yes/no)			0.002	0.907	0.071	< 0.001				
MetS (yes/no)			0.176	< 0.001	0.182	< 0.001				
Glucose							0.061	< 0.001	0.080	< 0.001
Non-HDL cholesterol (mmol/L)							0.472	< 0.001		
HDL cholesterol (mmol/L)							0.094	< 0.001		
ApoB (g/L)									0.358	< 0.001
ApoA-1 (g/L)									0.089	< 0.001
Alcoholic intake (≥ 10 g/day)			-0.004	0.792	-0.005	0.725	-0.017	0.189	-0.023	0.070
Current smoking (yes/no)			0.027	0.043	0.027	0.050	-0.007	0.579	-0.009	0.468
ApoE genotype $\epsilon 2\epsilon 2$ vs. $\epsilon 3\epsilon 3$			0.295	< 0.001	0.296	< 0.001	0.320	< 0.001	0.343	< 0.001
ApoE genotype $\epsilon 2\epsilon 3$ vs. $\epsilon 3\epsilon 3$			0.223	< 0.001	0.224	< 0.001	0.278	< 0.001	0.272	< 0.001
ApoE genotype $\epsilon 2\epsilon 4$ vs. $\epsilon 3\epsilon 3$			0.100	< 0.001	0.099	< 0.001	0.108	< 0.001	0.114	< 0.001
ApoE genotype $\epsilon 3\epsilon 4$ vs. $\epsilon 3\epsilon 3$			-0.070	< 0.001	-0.070	< 0.001	-0.095	< 0.001	-0.085	< 0.001
ApoE genotype $\epsilon 4\epsilon 4$ vs. $\epsilon 3\epsilon 3$			-0.070	< 0.001	-0.069	< 0.001	-0.089	< 0.001	-0.085	< 0.001
eGFR (ml/min/1.73 m ²)					-0.012	0.492				
UAE (mg/24 hr)					0.042	0.002				
History of cardiovascular disease					-0.026	0.065				
Use of antihypertensive medication					-0.020	0.186				
Use of glucose lowering drugs					-0.094	< 0.001				
Use of lipid lowering drugs					-0.003	0.817				

β : standardized regression coefficients. ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ApoE, apolipoprotein E; eGFR, estimated glomerular filtration rate; FLI, Fatty Liver Index; HDL, high density lipoproteins; MetS, metabolic syndrome; T2D, type 2 diabetes mellitus; UAE; urinary albumin excretion. The ApoE $\epsilon 3\epsilon 3$ genotype was used as reference category for the various ApoE genotypes.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, T2D, MetS, alcoholic intake, current smoking and ApoE genotype.

Model 3: adjusted for age, sex, T2D, MetS, alcoholic intake, current smoking, ApoE genotype, history of cardiovascular disease, eGFR, UAE and use of antihypertensive medication, glucose lowering and lipid lowering drugs.

Model 4: adjusted for age, sex, glucose, non-HDL cholesterol, HDL cholesterol, alcoholic intake, current smoking and ApoE genotype.

Model 5: adjusted for age, sex, glucose, ApoB, ApoA-1, alcoholic intake, current smoking and ApoE genotype.

<https://doi.org/10.1371/journal.pone.0220659.t002>

recognized determinant of VLDL and hence of triglyceride metabolism, are positively associated with NAFLD. In our study, we used an elevated FLI [48], and in alternative analyses an elevated HSI [50], as proxies of NAFLD, in line with international guidelines, which recommend using biomarkers in order to categorize subjects with probable NAFLD in large-scale studies [49]. In multivariable linear regression analyses, plasma ApoE levels remained positively associated with an elevated FLI when taking account of the various ApoE genotypes, T2D, MetS, glucose, non-HDL cholesterol, ApoB and other relevant covariates. Analyses with an elevated HSI instead of an elevated FLI iterated these findings. Furthermore, in a sensitivity analysis, excluding subjects with a cardiovascular history, impaired eGFR, elevated UAE and use of medication, as well as in analyses stratified for ApoE genotypes (ApoE $\epsilon 3\epsilon 3$ homozygotes, ApoE $\epsilon 2$ carriers and ApoE $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$ combined) an independent positive

Table 3. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Hepatic Steatosis Index (HSI) (> 36) after adjustment for clinical and laboratory covariates in 6,762 subjects.

	Model 1		Model 2		Model 3		Model 4		Model 5	
	β	P	β	P	β	P	β	P	β	P
Age	0.168	< 0.001	0.105	< 0.001	0.105	< 0.001	-0.012	0.373	0.034	0.012
Sex (men vs. women)	0.029	0.013	0.039	0.005	0.039	0.004	0.009	0.509	0.023	0.096
HSI > 36 vs. \leq 36	0.176	< 0.001	0.084	< 0.001	0.080	< 0.001	0.074	< 0.001	0.099	< 0.001
T2D (yes/no)			-0.007	0.607	0.068	0.001				
MetS (yes/no)			0.253	< 0.001	0.257	< 0.001				
Glucose							0.075	< 0.001	0.096	< 0.001
Non-HDL cholesterol (mmol/L)							0.500	< 0.001		
HDL cholesterol (mmol/L)							0.071	< 0.001		
ApoB (g/L)									0.394	< 0.001
ApoA-1 (g/L)									0.076	< 0.001
Alcoholic intake (\geq 10 g/day)			0.003	0.853	0.001	0.916	-0.009	0.469	-0.017	0.202
Current smoking (yes/no)			0.038	0.006	0.036	0.009	-0.003	0.841	-0.002	0.894
ApoE genotype ϵ2ϵ2 vs. ϵ3ϵ3			0.296	< 0.001	0.297	< 0.001	0.323	< 0.001	0.349	< 0.001
ApoE genotype ϵ2ϵ3 vs. ϵ3ϵ3			0.225	< 0.001	0.226	< 0.001	0.284	< 0.001	0.280	< 0.001
ApoE genotype ϵ2ϵ4 vs. ϵ3ϵ3			0.102	< 0.001	0.100	< 0.001	0.109	< 0.001	0.116	< 0.001
ApoE genotype ϵ3ϵ4 vs. ϵ3ϵ3			-0.069	< 0.001	-0.069	< 0.001	-0.096	< 0.001	-0.085	< 0.001
ApoE genotype ϵ4ϵ4 vs. ϵ3ϵ3			-0.067	< 0.001	-0.066	< 0.001	-0.088	< 0.001	-0.084	< 0.001
eGFR (ml/min/1.73 m ²)					-0.016	0.373				
UAE (mg/24 hr)					0.047	0.001				
History of cardiovascular disease					-0.027	0.060				
Use of antihypertensive medication					-0.015	0.310				
Use of glucose lowering drugs					-0.101	< 0.001				
Use of lipid lowering drugs					-0.007	0.637				

β : standardized regression coefficients. ApoA-1, apolipoprotein A-1; ApoB, apolipoprotein B; ApoE, apolipoprotein E; eGFR, estimated glomerular filtration rate; HDL, high density lipoproteins; HSI, Hepatic Steatosis Index; MetS, metabolic syndrome; T2D, type 2 diabetes mellitus; UAE; urinary albumin excretion. The ApoE ϵ 3 ϵ 3 genotype was used as reference category for the various ApoE genotypes.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, T2D, MetS, alcoholic intake, current smoking and ApoE genotype.

Model 3: adjusted for age, sex, T2D, MetS, alcoholic intake, current smoking, ApoE genotype, history of cardiovascular disease, eGFR, UAE and use of antihypertensive medication, glucose lowering and lipid lowering drugs.

Model 4: adjusted for age, sex, glucose, non-HDL cholesterol, HDL cholesterol, alcoholic intake, current smoking and ApoE genotype.

Model 5: adjusted for age, sex, glucose, ApoB, ApoA-1, alcoholic intake, current smoking and ApoE genotype.

<https://doi.org/10.1371/journal.pone.0220659.t003>

association of plasma ApoE levels with an elevated FLI was also demonstrated. Taken together, the present report thus suggests that higher plasma ApoE levels are increased in the context of an elevated FLI, as a proxy of NAFLD.

Imbalances between fatty acid influx, utilization and triglyceride synthesis leads to hepatic steatosis by accumulation of triglycerides and cholesteryl esters in hepatocytes [11–14,57]. Also the impact of hepatic fat accumulation on enhanced VLDL secretion is well established, as evidenced by higher VLDL and ApoB production rates in the context of hepatic fat accumulation [11–14]. The liver is a major source of ApoE, which controls intracellular lipid metabolism and VLDL assembly [57]. In murine models of ApoE deficiency and ApoE overexpression as well as in *in vitro* experiments, ApoE has been identified as an important regulator of hepatic VLDL assembly and secretion [57–59]. A link between ApoE and VLDL secretion has also

Table 4. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) (≥ 60) after adjustment for clinical and laboratory covariates in 3,501 subjects, excluding subjects with alcoholic intake ≥ 10 g/day, a positive cardiovascular history, impaired estimated glomerular filtration rate (< 60 mL/min/1.73 m²), elevated urinary albumin excretion (> 30 mg/24 hr), use of antihypertensive drugs, glucose lowering drugs and lipid lowering drugs.

	Model 1		Model 2		Model 3	
	β	P	β	P	β	P
Age	0.167	< 0.001	0.156	< 0.001	0.146	< 0.001
Sex (men vs. women)	-0.032	0.047	-0.018	0.354	0.011	0.517
FLI ≥ 60 vs. < 60	0.283	< 0.001	0.197	< 0.001	0.191	< 0.001
T2D (yes/no)			0.029	0.137	0.028	0.102
MetS (yes/no)			0.154	< 0.001	0.153	< 0.001
Current smoking (yes/no)			0.009	0.653	0.013	0.430
ApoE genotype $\epsilon 2\epsilon 2$ vs. $\epsilon 3\epsilon 3$					0.359	< 0.001
ApoE genotype $\epsilon 2\epsilon 3$ vs. $\epsilon 3\epsilon 3$					0.248	< 0.001
ApoE genotype $\epsilon 2\epsilon 4$ vs. $\epsilon 3\epsilon 3$					0.107	< 0.001
ApoE genotype $\epsilon 3\epsilon 4$ vs. $\epsilon 3\epsilon 3$					-0.100	< 0.001
ApoE genotype $\epsilon 4\epsilon 4$ vs. $\epsilon 3\epsilon 3$					-0.088	< 0.001

β : standardized regression coefficients. ApoE, apolipoprotein E; FLI, Fatty Liver Index; MetS, metabolic syndrome; T2D, type 2 diabetes mellitus. The ApoE $\epsilon 3\epsilon 3$ genotype was used as reference category for the various ApoE genotypes.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, T2D, MetS and current smoking.

Model 3: adjusted for age, sex, T2D, MetS, current smoking and ApoE genotype.

<https://doi.org/10.1371/journal.pone.0220659.t004>

been demonstrated in humans [57,60–62]. Furthermore, ApoE also plays an important role in VLDL clearance with the liver being the major site for the metabolism of ApoE-containing lipoproteins [14,18,63,64]. In an ApoE genotype-dependent fashion, ApoE has key functions in the binding and uptake of circulating lipoproteins which arise largely from its role in promoting clearance of TRL from the circulation involving the LDL receptor, the low density lipoprotein receptor-related protein 1 and heparan sulphate proteoglycans [63,64]. Additionally, ApoE may also affect TRL lipolysis [64]. The current report makes it plausible that a higher plasma ApoE level is a feature of NAFLD, conceivably by affecting VLDL metabolism although the precise mechanisms responsible for the association of higher plasma ApoE with NAFLD remain to be established.

Previous small-scale studies on the possible association of ApoE genotype variation with NAFLD showed conflicting results: no association of the different ApoE alleles with NAFLD [39], a possible protective effect of the ApoE $\epsilon 4$ allele against NAFLD [38,43], a possible protective effect of the ApoE $\epsilon 2$ allele and ApoE $\epsilon 2\epsilon 3$ genotype in non-obese NAFLD subjects [40], a higher risk for advanced fibrosis in ApoE $\epsilon 4$ carriers compared with $\epsilon 3$ carriers [41] and an association of increased NASH formation in the ApoE $\epsilon 3\epsilon 3$ genotype [42]. In our study, multivariable linear regression analysis demonstrated that plasma ApoE was higher in ApoE $\epsilon 2$ allele carriers and lower in ApoE $\epsilon 4$ allele carriers compared with ApoE $\epsilon 3$ allele carriers as expected [33]. No significant difference was found in the ApoE genotype distribution between individuals with and without suspected NAFLD, suggesting that ApoE gene variation as such has no major impact on NAFLD development. The differences between the present study and previous reports could in part be explained by the small number of study participants in these earlier studies [39–43], different approaches for NAFLD diagnosis and differences in ethnical background i.e. Dutch-Caucasian vs. Turkish, Italian, Polish or Korean populations. Earlier reports demonstrated a lower hepatic VLDL ApoB production rate in

ApoE $\epsilon 2$ homozygotes and ApoE $\epsilon 4$ homozygotes compared with ApoE $\epsilon 3$ homozygotes [60], and a lower VLDL ApoB production rate in ApoE $\epsilon 4$ carriers compared with ApoE $\epsilon 3$ homozygotes [62]. In the current study, plasma ApoE was also positively associated with an elevated FLI in analyses stratified for different ApoE genotype groups ($\epsilon 3\epsilon 3$ homozygotes, $\epsilon 2$ and $\epsilon 4$ carriers).

It is plausible to postulate that the association of plasma ApoE with NAFLD as shown in this report could influence the alleged effect of NAFLD on atherosclerosis susceptibility. Plasma ApoE levels predict incident CVD which is probably explained at least in part by the association of ApoE levels with atherogenic TRL [28,65,66]. In addition, ApoE has a potential role in dysfunctional transformation of HDL [29,30]. ApoE exerts anti-oxidative properties as well [22], and stabilizes the activity of paraoxonase-1 (PON-1), an HDL associated enzyme with anti-oxidative properties [67,68]. Serum PON-1 activity is indeed positively correlated with ApoE, but this relationship was found to be abolished in MetS, probably consequent to MetS-associated abnormalities in HDL [26].

Several strengths, limitations and methodological aspects of the present study need to be discerned. First, we performed a cross-sectional analysis. For this reason cause-effect relationships cannot be established with certainty, nor can we exclude the possibility of reversed causation. Thus while our study was analyzed with plasma ApoE as independent variable, it is also possible that circulating ApoE levels as such may represent a determinant of hepatic fat accumulation. Second, an elevated FLI was chosen as a proxy of suspected NAFLD. The FLI is considered to have sufficient accuracy for NAFLD assessment, and its use is in line with international guidelines to apply biomarker scores in order to characterize NAFLD in larger-sized cohorts and seems to perform best in European subjects, which is probably related to the ethnical difference in fat distribution [48,49]. Moreover, the positive association of plasma ApoE levels with suspected NAFLD, was confirmed by using the HSI as an alternative algorithm for NAFLD categorization [50], where it should be noted that the HSI has only been validated in a Korean population with a non-Caucasian background [50]. Also, analysis with a lower cut-off for excluding suspected NAFLD (FLI < 30 and HSI < 30), showed even stronger associations with plasma ApoE. Performing liver ultrasound or liver biopsy for the diagnosis of NAFLD, was not feasible in the PREVENT cohort study, which recruited individuals from the general population. Third, we could not differentiate between simple hepatic steatosis and hepatic fibrosis; therefore, no relationship of hepatic fibrosis with plasma ApoE levels could be established. Fourth, to preclude interactions with the FLI in the statistical analysis, variables making part of the FLI equation (i.e. triglycerides) were excluded as independent variables in multivariable analyses. Instead, we used i) metabolic syndrome categorization, ii) non-HDL cholesterol or iii) alternatively plasma ApoB as measures of ApoB-containing lipoproteins in subsidiary analyses. Fifth, we adjusted for HDL cholesterol as well, reasoning that these lipoproteins also carry ApoE [27]. Finally, the proportion of subjects using alcohol in excess of 30 gram per day in the PREVENT cohort is low, i.e. about 5.2% [69]. We adjusted for alcohol consumption in all analyses, and ApoE was unrelated to alcohol consumption. Also, the association of an elevated FLI with plasma ApoE remained present in analysis in which we excluded subjects with alcoholic intake ≥ 10 g/day. Finally, people with microalbuminuria preferentially participated in the PREVENT cohort. Therefore, we adjusted for eGFR and UAE in multivariable regression analysis and carried out a sensitivity analysis excluding subjects with impaired eGFR and elevated UAE. Reassuringly these analyses showed similar positive and independent associations of plasma ApoE levels with suspected NAFLD.

In conclusion, this study shows that suspected NAFLD is characterized by increased plasma ApoE levels, which conceivably contribute to altered VLDL metabolism in NAFLD.

Supporting information

S1 Table. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) ≥ 60 in 1,834 subjects compared with FLI < 30 in 3,270 subjects after adjustment for clinical and laboratory covariates.

(DOCX)

S2 Table. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Hepatic Steatosis Index (HSI) (> 36) in 1,862 subjects compared with HSI < 30 in 1,465 subjects after adjustment for clinical and laboratory covariates.

(DOCX)

S3 Table. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) (≥ 60) after adjustment for clinical and laboratory covariates in 3,577 subjects with apolipoprotein E genotype $\epsilon 3\epsilon 3$.

(DOCX)

S4 Table. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) (≥ 60) after adjustment for clinical and laboratory covariates in 1,010 subjects with apolipoprotein E $\epsilon 2$ carriers ($\epsilon 2\epsilon 2$, $\epsilon 2\epsilon 3$ and $\epsilon 2\epsilon 4$ genotypes combined).

(DOCX)

S5 Table. Multivariable regression analysis demonstrating the positive association of plasma apolipoprotein E with an elevated Fatty Liver Index (FLI) (≥ 60) after adjustment for clinical and laboratory covariates in 1,757 subjects with apolipoprotein E genotype $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$.

(DOCX)

S1 Data. Database.

(SAV)

Acknowledgments

Dr. J.E. Kootstra-Ros, Laboratory Center, University Medical Center Groningen, supervised performance of the liver function tests.

Author Contributions

Conceptualization: Eline H. van den Berg, Stephan J. L. Bakker, Robin P. F. Dullaart.

Data curation: Eline H. van den Berg, James P. Corsetti, Stephan J. L. Bakker, Robin P. F. Dullaart.

Formal analysis: Eline H. van den Berg, Robin P. F. Dullaart.

Funding acquisition: Stephan J. L. Bakker.

Investigation: Eline H. van den Berg, James P. Corsetti, Stephan J. L. Bakker, Robin P. F. Dullaart.

Methodology: Eline H. van den Berg, James P. Corsetti, Stephan J. L. Bakker, Robin P. F. Dullaart.

Resources: Stephan J. L. Bakker, Robin P. F. Dullaart.

Supervision: Stephan J. L. Bakker, Robin P. F. Dullaart.

Visualization: Eline H. van den Berg, James P. Corsetti, Stephan J. L. Bakker, Robin P. F. Dullaart.

Writing – original draft: Eline H. van den Berg, Robin P. F. Dullaart.

Writing – review & editing: Eline H. van den Berg, James P. Corsetti, Stephan J. L. Bakker, Robin P. F. Dullaart.

References

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol*. Nature Publishing Group; 2013; 10: 686–690. <https://doi.org/10.1038/nrgastro.2013.171> PMID: 24042449
2. Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. *World J Hepatol*. 2017; 9: 715–732. <https://doi.org/10.4254/wjh.v9.i16.715> PMID: 28652891
3. Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? *Eur J Intern Med*. 2017; 46: 1–5. <https://doi.org/10.1016/j.ejim.2017.06.024> PMID: 28688543
4. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. *Hepatology*. 2005; 42: 987–1000. <https://doi.org/10.1002/hep.20920> PMID: 16250043
5. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *J Gastroenterol Hepatol*. 2016; 31: 936–944. <https://doi.org/10.1111/jgh.13264> PMID: 26667191
6. Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, et al. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. *J Clin Endocrinol Metab*. 2016; 101: 644–652. <https://doi.org/10.1210/jc.2015-3111> PMID: 26672634
7. Nass KJ, van den Berg EH, Faber KN, Schreuder TCMA, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. *Metab Clin Exp*. 2017; 72: 37–46. <https://doi.org/10.1016/j.metabol.2017.04.004> PMID: 28641782
8. van den Berg EH, Amini M, Schreuder TCMA, Dullaart RPF, Faber KN, Alizadeh BZ, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. *PLoS ONE*. 2017; 12: e0171502. <https://doi.org/10.1371/journal.pone.0171502> PMID: 28152105
9. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. *World J Gastroenterol*. 2007; 13: 1579–1584. PMID: 17461452
10. Kunutsor SK, Bakker SJL, Blokzijl H, Dullaart RPF. Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. *Clin Chim Acta*. 2017; 466: 54–60. <https://doi.org/10.1016/j.cca.2017.01.008> PMID: 28082024
11. Adiels M, Taskinen M-R, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. *Diabetologia*. 2006; 49: 755–765. <https://doi.org/10.1007/s00125-005-0125-z> PMID: 16463046
12. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. *Gastroenterology*. 2008; 134: 424–431. <https://doi.org/10.1053/j.gastro.2007.11.038> PMID: 18242210
13. Cali AMG, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Otvos JD, et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. *Diabetes Care*. 2007; 30: 3093–3098. <https://doi.org/10.2337/dc07-1088> PMID: 17717283
14. Jiang ZG, Tapper EB, Connelly MA, Pimentel CFMG, Feldbrügge L, Kim M, et al. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. *Liver Int*. 2016; 36: 1213–1220. <https://doi.org/10.1111/liv.13076> PMID: 26815314
15. Rall SC, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. *J Biol Chem*. 1982; 257: 4171–4178. PMID: 7068630
16. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insight from animal and human studies. *Clin Chim Acta*. 1999; 286: 115–143. [https://doi.org/10.1016/s0009-8981\(99\)00097-2](https://doi.org/10.1016/s0009-8981(99)00097-2) PMID: 10511288

17. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. *J Mol Med*. 2005; 83: 329–342. <https://doi.org/10.1007/s00109-004-0631-3> PMID: 15827760
18. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. *J Lipid Res*. 2009; 50 Suppl: S183–8. <https://doi.org/10.1194/jlr.R800069-JLR200> PMID: 19106071
19. Luc G, Ducimetiere P, Bard JM, Arveiler D, Evans A, Cambien F, et al. Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. *Atherosclerosis*. 1997; 131: 257–262. [https://doi.org/10.1016/s0021-9150\(97\)00053-1](https://doi.org/10.1016/s0021-9150(97)00053-1) PMID: 9199280
20. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. *Trends Biochem Sci*. 2006; 31: 445–454. <https://doi.org/10.1016/j.tibs.2006.06.008> PMID: 16820298
21. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. *Curr Opin Lipidol*. 2000; 11: 243–251. PMID: 10882339
22. Jofre-Monseny L, Miniñane A-M, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. *Mol Nutr Food Res*. 2008; 52: 131–145. <https://doi.org/10.1002/mnfr.200700322> PMID: 18203129
23. Huang Y, Liu XQ, Rall SC, Taylor JM, Eckardstein von A, Assmann G, et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. *J Biol Chem*. 1998; 273: 26388–26393. <https://doi.org/10.1074/jbc.273.41.26388> PMID: 9756870
24. Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. *J Lipid Res*. 2000; 41: 706–718. PMID: 10787431
25. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J, et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. *Arterioscler Thromb Vasc Biol*. 1996; 16: 149–159. PMID: 8548416
26. Dullaart RPF, Kwakernaak AJ, Dallinga-Thie GM. The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. *Atherosclerosis*. 2013; 230: 6–11. <https://doi.org/10.1016/j.atherosclerosis.2013.06.019> PMID: 23958245
27. Söderlund S, Watanabe H, Ehnholm C, Jauhiainen M, Taskinen M-R. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. *Metab Clin Exp*. 2010; 59: 1502–1509. <https://doi.org/10.1016/j.metabol.2010.01.015> PMID: 20206948
28. Corsetti JP, Gansevoort RT, Bakker SJL, Dullaart RPF. Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study. *J Clin Lipidol*. 2016; 10: 842–850. <https://doi.org/10.1016/j.jacl.2016.03.003> PMID: 27578115
29. Corsetti JP, Gansevoort RT, Bakker SJL, Navis G, Sparks CE, Dullaart RPF. Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein. *Metab Clin Exp*. 2012; 61: 996–1002. <https://doi.org/10.1016/j.metabol.2011.11.010> PMID: 22225956
30. Corsetti JP, Bakker SJL, Sparks CE, Dullaart RPF. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. *PLoS ONE*. 2012; 7: e39110. <https://doi.org/10.1371/journal.pone.0039110> PMID: 22723940
31. Myklebost O, Rogne S. A physical map of the apolipoprotein gene cluster on human chromosome 19. *Hum Genet*. 1988; 78: 244–247. <https://doi.org/10.1007/bf00291670> PMID: 2894348
32. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. *Genomics*. 1995; 28: 291–300. <https://doi.org/10.1006/geno.1995.1144> PMID: 8530039
33. Smit M, de Knijff P, Rosseneu M, Bury J, Klasen E, Frants R, et al. Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. *Hum Genet*. 1988; 80: 287–292. <https://doi.org/10.1007/bf01790099> PMID: 3192216
34. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. *Am J Hum Genet*. 1988; 42: 104–112. PMID: 3337104
35. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *JAMA*. 2007; 298: 1300–1311. <https://doi.org/10.1001/jama.298.11.1300> PMID: 17878422
36. Karavia EA, Papachristou DJ, Kotsikogianni I, Giopanou I, Kypreos KE. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice. *FEBS J*. 2011; 278: 3119–3129. <https://doi.org/10.1111/j.1742-4658.2011.08238.x> PMID: 21740524

37. Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, et al. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. *Sci Rep*. 2015; 5: 12931. <https://doi.org/10.1038/srep12931> PMID: 26263022
38. Yang MH, Son HJ, Sung JD, Choi YH, Koh KC, Yoo BC, et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. *Hepatogastroenterology*. 2005; 52: 1832–1835. PMID: 16334787
39. Lee D-M, Lee S-O, Mun B-S, Ahn H-S, Park H-Y, Lee H-S, et al. [Relation of apolipoprotein E polymorphism to clinically diagnosed fatty liver disease]. *Taehan Kan Hakhoe Chi*. 2002; 8: 355–362. PMID: 12506239
40. Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, et al. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. *Dig Dis Sci*. 2007; 52: 3399–3403. <https://doi.org/10.1007/s10620-007-9740-5> PMID: 17431774
41. Stachowska E, Maciejewska D, Ossowski P, Drozd A, Ryterska K, Banaszczyk M, et al. Apolipoprotein E4 allele is associated with substantial changes in the plasma lipids and hyaluronic acid content in patients with nonalcoholic fatty liver disease. *J Physiol Pharmacol*. 2013; 64: 711–717. PMID: 24388885
42. Sazci A, Akpınar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. *Dig Dis Sci*. 2008; 53: 3218–3224. <https://doi.org/10.1007/s10620-008-0271-5> PMID: 18465245
43. De Feo E, Cefalo C, Arzani D, Amore R, Landolfi R, Grieco A, et al. A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. *Mol Biol Rep*. 2012; 39: 7381–7388. <https://doi.org/10.1007/s11033-012-1570-7> PMID: 22350157
44. Kappelle PJWH, Gansevoort RT, Hillege JL, Wolffenbuttel BHR, Dullaart RPF, PREVEND study group. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. *J Intern Med*. 2011; 269: 232–242. <https://doi.org/10.1111/j.1365-2796.2010.02323.x> PMID: 21129046
45. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Bakker SJL, van der Steege G, et al. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. *J Clin Endocrinol Metab*. 2005; 90: 4198–4204. <https://doi.org/10.1210/jc.2005-0182> PMID: 15840744
46. van den Berg EH, Gruppen EG, James RW, Bakker SJL, Dullaart RPF. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. *J Lipid Res*. 2019; 60: 168–175. <https://doi.org/10.1194/jlr.P088997> PMID: 30455362
47. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012; 367: 20–29. <https://doi.org/10.1056/NEJMoa1114248> PMID: 22762315
48. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol*. 2006; 6: 33. <https://doi.org/10.1186/1471-230X-6-33> PMID: 17081293
49. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Diabetologia*. 2016; 59: 1121–1140. <https://doi.org/10.1007/s00125-016-3902-y> PMID: 27053230
50. Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Dig Liver Dis*. 2010; 42: 503–508. <https://doi.org/10.1016/j.dld.2009.08.002> PMID: 19766548
51. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005; 112: 2735–2752. <https://doi.org/10.1161/CIRCULATIONAHA.105.169404> PMID: 16157765
52. Blaauwwekel EE, Beusekamp BJ, Sluiter WJ, Hoogenberg K, Dullaart RP. Apolipoprotein E genotype is a determinant of low-density lipoprotein cholesterol and of its response to a low-cholesterol diet in Type 1 diabetic patients with elevated urinary albumin excretion. *Diabet Med*. 1998; 15: 1031–1035. [https://doi.org/10.1002/\(SICI\)1096-9136\(1998120\)15:12<1031::AID-DIA705>3.0.CO;2-6](https://doi.org/10.1002/(SICI)1096-9136(1998120)15:12<1031::AID-DIA705>3.0.CO;2-6) PMID: 9868977
53. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972; 18: 499–502. PMID: 4337382
54. Schumann G, Bonora R, Ceriotti F, Féraud G, Ferrero CA, Franck PFH, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C.

- International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. *Clinical chemistry and laboratory medicine*. 2002; pp. 718–724. <https://doi.org/10.1515/CCLM.2002.124> PMID: 12241021
55. Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PFH, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. *Clinical chemistry and laboratory medicine*. 2002; pp. 725–733. <https://doi.org/10.1515/CCLM.2002.125> PMID: 12241022
 56. Schumann G, Bonora R, Ceriotti F, Férard G, Ferrero CA, Franck PFH, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 6. Reference procedure for the measurement of catalytic concentration of gamma-glutamyltransferase. *Clinical chemistry and laboratory medicine*. 2002; pp. 734–738. <https://doi.org/10.1515/CCLM.2002.126> PMID: 12241023
 57. Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. *J Hepatol*. 2001; 35: 816–822. PMID: 11738112
 58. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. *Annu Rev Nutr*. 1995; 15: 495–518. <https://doi.org/10.1146/annurev.nu.15.070195.002431> PMID: 8527231
 59. Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. *J Biol Chem*. 1999; 274: 35711–35718. <https://doi.org/10.1074/jbc.274.50.35711> PMID: 10585451
 60. Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. *J Clin Invest*. 1991; 88: 1490–1501. <https://doi.org/10.1172/JCI115459> PMID: 1939641
 61. Riches FM, Watts GF, van Bockxmeer FM, Hua J, Song S, Humphries SE, et al. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. *J Lipid Res*. 1998; 39: 1752–1758. PMID: 9741687
 62. Welty FK, Lichtenstein AH, Barrett PH, Jenner JL, Dolnikowski GG, Schaefer EJ. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. *Arterioscler Thromb Vasc Biol*. 2000; 20: 1807–1810. PMID: 10894821
 63. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. *J Lipid Res*. 2009; 50 Suppl: S156–61. <https://doi.org/10.1194/jlr.R800058-JLR200> PMID: 19018038
 64. Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. *IUBMB Life*. 2014; 66: 616–623. <https://doi.org/10.1002/iub.1314> PMID: 25328986
 65. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population. *Atherosclerosis*. 2016; 246: 63–70. <https://doi.org/10.1016/j.atherosclerosis.2015.12.038> PMID: 26761769
 66. Mooijaart SP, Berbée JFP, van Heemst D, Havekes LM, de Craen AJM, Slagboom PE, et al. ApoE plasma levels and risk of cardiovascular mortality in old age. *PLoS Med*. 2006; 3: e176. <https://doi.org/10.1371/journal.pmed.0030176> PMID: 16671834
 67. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. *Biochemistry*. 2005; 44: 11843–11854. <https://doi.org/10.1021/bi050862i> PMID: 16128586
 68. Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, Handattu SP, et al. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. *Atherosclerosis*. 2012; 224: 326–331. <https://doi.org/10.1016/j.atherosclerosis.2012.05.040> PMID: 22771190
 69. Gruppen EG, Bakker SJL, James RW, Dullaart RPF. Serum paraoxonase-1 activity is associated with light to moderate alcohol consumption: the PREVENT cohort study. *Am J Clin Nutr*. 2018. <https://doi.org/10.1093/ajcn/nqy217> PMID: 30376039